CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Sweden's Aino Health Q3 losses widen on marketing investments

By Reuters News


Overview

  • Sweden SaaS health platform's Q3 net sales rose 5.6% yr/yr, losses widened

  • Company announced major new agreement with HUS Group to expand SaaS subscriptions

  • HealthCo Oy completed tender offer, now controls 84.2% of Aino Health shares


Outlook

  • Company expects SaaS subscription base to rise from 116,000 to around 142,500 after HUS Group deal

  • Company says continued cost discipline is essential due to constrained financial position

  • Aino Health sees international expansion and growth investments requiring sufficient financial capacity and possibly additional financing


Result Drivers

  • SAAS TRANSITION - Co said continued shift to SaaS-based business model supported net sales growth in Q3

  • SALES AND MARKETING INVESTMENTS - Increased spending on sales and marketing raised costs to support customer acquisition and international growth

  • SEASONAL VARIATION - Slight decrease in SaaS subscriptions from previous quarter attributed to normal seasonal variation in customer organisations


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

SEK 6.16 mln

Q3 EPS

SEK 0


Reuters Recommended Reads

  • Nov 12 - Sweden's Done.ai Q3 revenue rises 21%

  • Nov 12 - Sweden's cybersecurity firm Clavister Q3 net sales rise

  • Nov 9 - Israel's Monday.com Q3 revenue rises 19%


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.